.Nature Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free as well as overall survival, causing FDA commendation and a brand new therapy choice for people.